Evidence map›Paper›PMID 37522942›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2023

Estimating the disutility of relapse in relapsing-remitting and secondary progressive multiple sclerosis using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-psychosocial, and SF-6D: implications for health economic evaluation models.

Hasnat Ahmad, Julie A Campbell, Ingrid van der Mei, Bruce V Taylor, Qing Xia, Ting Zhao, Andrew J Palmer

Open access · hybridAbstract read
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Comparing EQ-5D-5L, PROPr, SF-6D and TTO utilities in patients with chronic skin diseases.The European journal of health economics : HEPAC : health economics in prevention and care · 2025
    Article
  4. Effect of impairment on health-related quality of life in people with multiple sclerosis: association of functional systems and EQ-5D-5L index values in a cross-sectional study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Article
  5. Estimated health and economic effects associated with over- and under-exposure to solar ultraviolet radiation in Australia and New Zealand using the SUNEX simulation model.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Hasnat Ahmad *Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia. hasnat.ahmed@utas.edu.au.ORCID http://orcid.org/0000-0002-2580-9856
Julie A Campbell *Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Ingrid van der MeiMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Bruce V TaylorMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Qing XiaAustralian Centre for Health Services Innovation and Centre for Healthcare Transformation, School of Public Health & Social Work, Queensland University of Technology, Brisbane, QLD, Australia.
Ting ZhaoMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
Andrew J PalmerMenzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
University of Tasmania · AUQueensland University of Technology · AU

Funding

Multiple Sclerosis Research Australia 19-0702
6 · The paper itself

Abstract

BACKGROUND AND

aimsRelapses are an important clinical feature of multiple sclerosis (MS) that result in temporary negative changes in quality of life (QoL), measured by health state utilities (HSUs) (disutilities). We aimed to quantify disutilities of relapse in relapsing remitting MS (RRMS), secondary progressive MS (SPMS), and relapse onset MS [ROMS (including both RRMS and SPMS)] and examine these values by disability severity using four multi-attribute utility instruments (MAUIs).

methodsWe estimated (crude and adjusted and stratified by disability severity) disutilities (representing the mean difference in HSUs of 'relapse' and 'no relapse' groups as well as 'unsure' and 'no relapse' groups) in RRMS (n = 1056), SPMS (n = 239), and ROMS (n = 1295) cohorts from the Australian MS Longitudinal Study's 2020 QoL survey, using the EQ-5D-5L, AQoL-8D, EQ-5D-5L-Psychosocial, and SF-6D MAUIs.

resultsAdjusted mean overall disutilities of relapse in RMSS/SPMS/ROMS were - 0.101/- 0.149/- 0.129 (EQ-5D-5L), - 0.092/- 0.167/- 0.113 (AQoL-8D), - 0.080/- 0.139/- 0.097 (EQ-5D-5L-Psychosocial), and - 0.116/- 0.161/- 0.130 (SF-6D), approximately 1.5 times higher in SPMS than in RRMS, in all MAUI. All estimates were statistically significant and/or clinically meaningful. Adjusted disutilities of RRMS and ROMS demonstrated a U-shaped relationship between relapse disutilities and disability severity. Relapse disutilities were higher in 'severe' disability than 'mild' and 'moderate' in the SPMS cohort.

conclusionMS-related relapses are associated with substantial utility decrements. As the type and severity of MS influence disutility of relapse, the use of disability severity and MS-type-specific disutility inputs is recommended in future health economic evaluations of MS. Our study supports relapse management and prevention as major mechanisms to improve QoL in people with MS.

Indexed as

Multiple SclerosisMultiple Sclerosis, Chronic ProgressiveAustraliaChronic DiseaseCost-Benefit AnalysisHumansLongitudinal StudiesQuality of LifeRecurrenceSurveys and QuestionnairesAQoL-8DCost–utility analysisDisutility of relapseEQ-5D-5L-psychosocialHealth-related quality of lifeMulti-attribute utility instrumentMultiple sclerosisSF-6D

Identifiers

PMID37522942
PMCPMC10624739
OpenAlexW4385405957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.